Precigen, Inc. (PGEN)

1,3300 -0,0500 (-3,62%) Al cierre: 04:00PM EDT

Precigen, Inc.

20358 Seneca Meadows Parkway
Germantown, MD 20876
United States
301 556 9900
https://precigen.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 202

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Randal J. Kirk J.D.	Executive Chairman	100k	N/A	1953
Dr. Helen Sabzevari MPH, Ph.D.	President, CEO & Director	1,02M	N/A	1962
Mr. Harry Thomasian Jr.	Chief Financial Officer	508,54k	N/A	1962
Mr. Rutul R. Shah	Chief Operating Officer	453,02k	N/A	1981
Mr. Donald P. Lehr	Chief Legal Officer & Corporate Secretary	618,32k	N/A	1975
Mr. Jeffrey Thomas Perez J.D.	Senior Vice President of Intellectual Property Affairs	540,67k	N/A	1972
Mr. Steven Harasym	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Rob Russell	VP & Head of Human Resources	N/A	N/A	N/A
Dr. Douglas E. Brough Ph.D.	Senior VP & Head of Research	N/A	N/A	1955
Dr. Bryan T. Butman Ph.D.	Senior VP & Head of CMC	N/A	N/A	1953

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Gobierno corporativo

El ISS Governance QualityScore de Precigen, Inc., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 8; Tablero: 6; Derechos de los accionistas: 3; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.